EU concludes talks with Sanofi to secure 300 mln doses of coronavirus vaccine
It is part of a broader European Union (EU) campaign seeking to reach purchase agreements with major COVID-19 vaccine manufacturers.
Sanofi's vaccine candidate is planning to seek marketing authorization from the European Medicines Agency in June 2021 following Phase III clinical trials.
The commission said in a statement that it would have a contractual framework in place for the purchase of 300 million doses on behalf of all EU member states once Sanofi's vaccine has proven to be safe and effective against COVID-19.
According to the EU strategy for COVID-19 vaccines, the commission would finance part of the upfront costs faced by vaccine producers in the form of Advance Purchase Agreements. Funding provided would be considered as a down payment on the vaccines to be purchased by the EU member states. ■